Pacira BioSciences (PCRX) Current Assets (2010 - 2026)

Pacira BioSciences' Current Assets history runs 17 years deep, the most recent figure standing at $515.0 million for Q1 2026.

• On a quarterly basis, Current Assets fell 32.24% year-over-year to $515.0 million in Q1 2026; TTM through Mar 2026 was $515.0 million, a 32.24% decrease from a year earlier, with the FY2025 full-year figure at $548.0 million, down 26.46% from the prior year.
• Current Assets slipped to $515.0 million in Q1 2026 per PCRX's latest filing, from $548.0 million in the prior quarter.
• Across five years, Current Assets topped out at $760.0 million in Q1 2025 and bottomed at $376.1 million in Q1 2023.
• The 5-year median for Current Assets is $543.1 million (2024), against an average of $572.3 million.
• Across the five-year window, Current Assets slumped 43.61% in 2023 and soared 54.27% in 2024, its largest moves.
• Year by year, Current Assets stood at $498.3 million in 2022, then climbed by 2.34% to $510.0 million in 2023, then soared by 46.11% to $745.1 million in 2024, then retreated by 26.46% to $548.0 million in 2025, then decreased by 6.02% to $515.0 million in 2026.
• Per Business Quant, the three latest PCRX Current Assets figures stand at $515.0 million (Q1 2026), $548.0 million (Q4 2025), and $562.8 million (Q3 2025).